{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:45:56Z","timestamp":1777556756840,"version":"3.51.4"},"reference-count":28,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,11,10]]},"DOI":"10.1253\/circrep.cr-25-0140","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T22:07:52Z","timestamp":1756764472000},"page":"1102-1108","source":"Crossref","is-referenced-by-count":1,"title":["Effect of \u03b2-Blockers on the Left Ventricular Strain in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis"],"prefix":"10.1253","volume":"7","author":[{"given":"Rosy Haruna","family":"Nishizawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisa","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Yoshimuta","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"Kojima","sequence":"additional","affiliation":[{"name":"Ultrasound Imaging Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Okano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Maemura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nochioka K, Quarta CC, Claggett B, Roca GQ, Rapezzi C, Falk RH, et al. Left atrial structure and function in cardiac amyloidosis. <i>Eur Heart J Cardiovasc Imaging<\/i> 2017; 18: 1128\u20131137.","DOI":"10.1093\/ehjci\/jex097"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A Position Statement of the ESC Working Group on Myocardial and Pericardial Diseases. <i>Eur Heart J<\/i> 2021; 42: 1554\u20131568.","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Otsuka K, Kawano H, Koike H, Sueyoshi E, Arakawa S, Fukae S, et al. Atrial lesion and diastolic dysfunction may be associated with atrial fibrillation in patients with cardiac amyloidosis. <i>Circ Rep<\/i> 2024; 6: 539\u2013546.","DOI":"10.1253\/circrep.CR-24-0116"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Minamisawa M, Inciardi RM, Claggett B, Cuddy SAM, Quarta CC, Shah AM, et al. Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans. <i>Eur J Heart Fail<\/i> 2021; 23: 1290\u20131295.","DOI":"10.1002\/ejhf.2200"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Arima N, Ochi Y, Kubo T, Murakami Y, Nishino K, Yamamoto H, et al. Prospective multicenter screening with high-sensitivity cardiac troponin T for wild-type transthyretin cardiac amyloidosis in outpatient and community-based settings. <i>Circ J<\/i> 2024; 89: 24\u201330.","DOI":"10.1253\/circj.CJ-24-0479"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Miyamoto M, Nakamura K, Nakagawa K, Nishii N, Kawada S, Ueoka A, et al. Prevalence and treatment of arrhythmias in patients with transthyretin and light-chain cardiac amyloidosis. <i>Circ Rep<\/i> 2023; 5: 298\u2013305.","DOI":"10.1253\/circrep.CR-23-0022"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med<\/i> 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms. <i>Eur J Heart Fail<\/i> 2023; 25: 2060\u20132064.","DOI":"10.1002\/ejhf.2974"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takashio S, Morioka M, Ishii M, Morikawa K, Hirakawa K, Hanatani S, et al. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy. <i>ESC Heart Fail<\/i> 2023; 10: 2319\u20132329.","DOI":"10.1002\/ehf2.14380"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. <i>Eur J Heart Fail<\/i> 2021; 23: 277\u2013285.","DOI":"10.1002\/ejhf.2027"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Garcia-Pavia P, Sultan MB, Gundapaneni B, Sekijima Y, Perfetto F, Hanna M, et al. Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study. <i>JACC Heart Fail<\/i> 2024; 12: 150\u2013160.","DOI":"10.1016\/j.jchf.2023.08.032"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shah SJ, Fine N, Garcia-Pavia P, Klein AL, Fernandes F, Weissman NJ, et al. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: A post hoc analysis of the ATTR-ACT randomized clinical trial. <i>JAMA Cardiol<\/i> 2024; 9: 25\u201334.","DOI":"10.1001\/jamacardio.2023.4147"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sperry BW, Hanna M, Maurer MS, Nativi-Nicolau J, Floden L, Stewart M, et al. Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: A post hoc analysis of the ATTR-ACT randomized clinical trial. <i>JAMA Cardiol<\/i> 2023; 8: 275\u2013280.","DOI":"10.1001\/jamacardio.2022.5251"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Giblin GT, Cuddy SAM, Gonz\u00e1lez-L\u00f3pez E, Sewell A, Murphy A, Dorbala S, et al. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis. <i>Eur Heart J Cardiovasc Imaging<\/i> 2022; 23: 1029\u20131039.","DOI":"10.1093\/ehjci\/jeac049"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ichikawa Y, Oota E, Odajima S, Kintsu M, Todo S, Takeuchi K, et al. Impact of tafamidis on echocardiographic cardiac function of patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2023; 87: 508\u2013516.","DOI":"10.1253\/circj.CJ-22-0683"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Uemura K, Ichikawa Y, Nagai S, Nishihara Y, Todo S, Oota E, et al. Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy. <i>Heart Vessels<\/i> 2024; 39: 810\u2013817.","DOI":"10.1007\/s00380-024-02402-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Drachman B, Damy T, Hanna M, Wang R, Angeli FS, Garcia-Pavia P. Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction. <i>Eur J Heart Fail<\/i> 2024; 26: 2038\u20132046.","DOI":"10.1002\/ejhf.3330"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nishizawa RH, Kawano H, Yoshimuta T, Eguchi C, Kojima S, Minami T, et al. Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis. <i>Eur Heart J Cardiovasc Imaging<\/i> 2024; 25: 678\u2013686.","DOI":"10.1093\/ehjci\/jead344"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ohata T, Niimi N, Shiraishi Y, Nakatsu F, Umemura I, Kohno T, et al. Initiation and up-titration of guideline-based medications in hospitalized acute heart failure patients: A report from the West Tokyo Heart Failure Registry. <i>Circ J<\/i> 2023; 88: 22\u201330.","DOI":"10.1253\/circj.CJ-23-0356"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Matsukawa R, Kabu K, Koga E, Hara A, Kisanuki H, Sada M, et al. Optimizing guideline-directed medical therapy during hospitalization improves prognosis in patients with worsening heart failure requiring readmissions. <i>Circ J<\/i> 2024; 88: 1416\u20131424.","DOI":"10.1253\/circj.CJ-24-0265"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tini G, Cappelli F, Biagini E, Musumeci B, Merlo M, Crotti L, et al. Current patterns of beta-blocker prescription in cardiac amyloidosis: An Italian nationwide survey. <i>ESC Heart Fail<\/i> 2021; 8: 3369\u20133374.","DOI":"10.1002\/ehf2.13411"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>J Am Soc Echocardiogr<\/i> 2015; 28: 1\u201339.e14.","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management <i>Circulation<\/i> 2020; 142: e7\u2013e22.","DOI":"10.1161\/CIR.0000000000000792"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. <i>Circ J<\/i> 2020; 84: 1610\u20131671.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Barge-Caballero G, Barge-Caballero E, L\u00f3pez-P\u00e9rez M, Bilbao-Quesada R, Gonz\u00e1lez-Babarro E, G\u00f3mez-Otero I, et al. Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy. <i>Mayo Clin Proc<\/i> 2022; 97: 261\u2013273.","DOI":"10.1016\/j.mayocp.2021.08.006"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. <i>Eur Heart J<\/i> 2023; 44: 2893\u20132907.","DOI":"10.1093\/eurheartj\/ehad347"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kwok CS, Choy CH, Pinney J, Townend JN, Whelan C, Fontana M, et al. Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis. <i>ESC Heart Fail<\/i> 2024; 11: 3901\u20133910.","DOI":"10.1002\/ehf2.14975"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tanaka H. Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: Special focus on speckle-tracking longitudinal strain. <i>J Echocardiogr<\/i> 2021; 19: 71\u201379.","DOI":"10.1007\/s12574-020-00508-3"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/11\/7_CR-25-0140\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:24:27Z","timestamp":1763177067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/11\/7_CR-25-0140\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0140","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"CR-25-0140"}}